ZA201605342B - Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema - Google Patents
Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedemaInfo
- Publication number
- ZA201605342B ZA201605342B ZA201605342A ZA201605342A ZA201605342B ZA 201605342 B ZA201605342 B ZA 201605342B ZA 201605342 A ZA201605342 A ZA 201605342A ZA 201605342 A ZA201605342 A ZA 201605342A ZA 201605342 B ZA201605342 B ZA 201605342B
- Authority
- ZA
- South Africa
- Prior art keywords
- binding proteins
- plasma kallikrein
- hereditary angioedema
- kallikrein binding
- treating hereditary
- Prior art date
Links
- 206010019860 Hereditary angioedema Diseases 0.000 title 1
- 102000003827 Plasma Kallikrein Human genes 0.000 title 1
- 108090000113 Plasma Kallikrein Proteins 0.000 title 1
- 102000023732 binding proteins Human genes 0.000 title 1
- 108091008324 binding proteins Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/03—Phosphotransferases with a nitrogenous group as acceptor (2.7.3)
- C12Y207/03002—Creatine kinase (2.7.3.2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21034—Plasma kallikrein (3.4.21.34)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461929716P | 2014-01-21 | 2014-01-21 | |
| US201461944361P | 2014-02-25 | 2014-02-25 | |
| US201462021397P | 2014-07-07 | 2014-07-07 | |
| PCT/US2015/012212 WO2015112578A1 (en) | 2014-01-21 | 2015-01-21 | Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201605342B true ZA201605342B (en) | 2020-11-25 |
Family
ID=53681890
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA201605342A ZA201605342B (en) | 2014-01-21 | 2016-08-02 | Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema |
| ZA2020/04653A ZA202004653B (en) | 2014-01-21 | 2020-07-28 | Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2020/04653A ZA202004653B (en) | 2014-01-21 | 2020-07-28 | Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US11084884B2 (enExample) |
| EP (2) | EP3848057B1 (enExample) |
| JP (4) | JP6845012B2 (enExample) |
| KR (4) | KR20240049627A (enExample) |
| CN (2) | CN116585468A (enExample) |
| AU (3) | AU2015209481C1 (enExample) |
| BR (1) | BR112016016916B1 (enExample) |
| CA (1) | CA2937329C (enExample) |
| DK (1) | DK3096798T3 (enExample) |
| EA (1) | EA038532B1 (enExample) |
| ES (1) | ES2856076T3 (enExample) |
| IL (3) | IL246864B (enExample) |
| MX (2) | MX387753B (enExample) |
| NZ (2) | NZ761006A (enExample) |
| PL (1) | PL3096798T3 (enExample) |
| PT (1) | PT3096798T (enExample) |
| WO (1) | WO2015112578A1 (enExample) |
| ZA (2) | ZA201605342B (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20220107T1 (hr) | 2010-01-06 | 2022-04-15 | Takeda Pharmaceutical Company Limited | Proteini koji vežu kalikrein plazme |
| CN105713092B (zh) * | 2011-01-06 | 2019-09-10 | 戴埃克斯有限公司 | 血浆前激肽释放酶结合蛋白 |
| ES2692408T3 (es) | 2013-01-20 | 2018-12-03 | Dyax Corp. | Evaluación y tratamiento de trastornos mediados por bradiquinina |
| IL292121B2 (en) | 2013-03-15 | 2024-02-01 | Takeda Pharmaceuticals Co | Anti-plasma kallikrein antibodies |
| IL289514B2 (en) | 2013-10-21 | 2024-01-01 | Takeda Pharmaceuticals Co | Assays for determining plasma kallikrein system biomarkers |
| ES2873204T3 (es) | 2013-10-21 | 2021-11-03 | Takeda Pharmaceuticals Co | Diagnóstico y tratamiento de enfermedades autoinmunes |
| PT3096798T (pt) * | 2014-01-21 | 2021-02-25 | Dyax Corp | Proteínas de ligação à calicreína plasmática e seus usos no tratamento de angioedema hereditário |
| IL247942B (en) | 2014-03-27 | 2022-09-01 | Dyax Corp | Compositions and methods for drops in macular edema as a result of diabetes |
| CN107614532A (zh) * | 2015-03-30 | 2018-01-19 | 戴埃克斯有限公司 | 血浆激肽释放酶抑制剂及其预防遗传性血管性水肿发作的用途 |
| WO2017035263A1 (en) * | 2015-08-24 | 2017-03-02 | Biocryst Pharmaceuticals, Inc. | Compositions comprising a plasma kallikrein inhibitor |
| MX2018004763A (es) * | 2015-10-19 | 2018-09-06 | Dyax Corp | Inmunoensayo para detectar quininogeno escindido de alto peso molecular. |
| KR20250139401A (ko) * | 2015-12-11 | 2025-09-23 | 다케다 파머수티컬 컴패니 리미티드 | 혈장 칼리크레인 저해제 및 유전성 혈관부종 발작을 치료하기 위한 이의 용도 |
| EP3513196A1 (en) * | 2016-09-16 | 2019-07-24 | Dyax Corp. | Protein biomarkers for diseases associated with the contact activation system |
| CN117187377A (zh) | 2016-09-16 | 2023-12-08 | 武田药品工业株式会社 | 用于遗传性血管性水肿的rna生物标记 |
| WO2019079496A2 (en) * | 2017-10-18 | 2019-04-25 | Regenxbio, Inc. | FULLY HUMAN ANTIBODY-BASED THERAPEUTIC AGENTS HAVING POST-TRANSLATION MODIFICATION |
| KR102756073B1 (ko) | 2017-12-01 | 2025-01-20 | 쑤저우 리보 라이프 사이언스 컴퍼니, 리미티드 | 이중-가닥 올리고뉴클레오티드, 조성물 및 이중-가닥 올리고뉴클레오티드를 포함하는 접합체, 그의 제조 방법 및 그의 용도 |
| WO2019105419A1 (zh) | 2017-12-01 | 2019-06-06 | 苏州瑞博生物技术有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
| JP7261494B2 (ja) | 2017-12-01 | 2023-04-20 | スーチョウ リボ ライフ サイエンス カンパニー、リミテッド | 核酸、当該核酸を含む組成物及び複合体ならびに調製方法と使用 |
| WO2019105435A1 (zh) | 2017-12-01 | 2019-06-06 | 苏州瑞博生物技术有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
| US12083142B2 (en) | 2017-12-01 | 2024-09-10 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, composition and conjugate comprising the same, and preparation method and use thereof |
| HRP20250408T1 (hr) | 2017-12-29 | 2025-06-06 | Suzhou Ribo Life Science Co., Ltd. | Kojugati i njihova priprema i uporaba |
| US11918600B2 (en) | 2018-08-21 | 2024-03-05 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, pharmaceutical composition and conjugate containing nucleic acid, and use thereof |
| CN111655297A (zh) | 2018-09-30 | 2020-09-11 | 苏州瑞博生物技术有限公司 | 一种siRNA缀合物及其制备方法和用途 |
| US12163956B2 (en) | 2019-02-21 | 2024-12-10 | Takeda Pharmaceutical Company Limited | Lateral flow immunoassay for measuring functional C1-esterase inhibitor (C1-INH) in plasma samples |
| AU2020237259A1 (en) * | 2019-03-14 | 2021-10-14 | Takeda Pharmaceutical Company Limited | Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack |
| JP7614650B2 (ja) * | 2019-05-24 | 2025-01-16 | スーチョウ リボ ライフ サイエンス カンパニー、リミテッド | 核酸、薬物組成物及び複合体並びに調製方法と使用 |
Family Cites Families (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US5374548A (en) | 1986-05-02 | 1994-12-20 | Genentech, Inc. | Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor |
| MX9203291A (es) | 1985-06-26 | 1992-08-01 | Liposome Co Inc | Metodo para acoplamiento de liposomas. |
| US5444156A (en) * | 1985-07-12 | 1995-08-22 | Temple University-Of The Commonwealth System Of Higher Education | Monoclonal antibodies to human plasma prekallikrein |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| EP0296171A4 (en) | 1986-03-03 | 1989-11-07 | Brigham & Womens Hospital | ASSESSMENT PROCEDURE FOR NEPHROTOXICITY. |
| US4881175A (en) | 1986-09-02 | 1989-11-14 | Genex Corporation | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US4704692A (en) | 1986-09-02 | 1987-11-03 | Ladner Robert C | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| US5045452A (en) | 1988-09-02 | 1991-09-03 | Brigham And Women's Hospital | Method for evaluating nephrotoxicity |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| CA2103059C (en) | 1991-06-14 | 2005-03-22 | Paul J. Carter | Method for making humanized antibodies |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| US6057287A (en) | 1994-01-11 | 2000-05-02 | Dyax Corp. | Kallikrein-binding "Kunitz domain" proteins and analogues thereof |
| CA2180950C (en) | 1994-01-11 | 2005-03-29 | William Markland | Kallikrein-inhibiting "kunitz domain" proteins and analogues thereof |
| US6265150B1 (en) | 1995-06-07 | 2001-07-24 | Becton Dickinson & Company | Phage antibodies |
| DE19632772A1 (de) | 1996-08-14 | 1998-02-19 | Basf Ag | Neue Benzamidine |
| US5840871A (en) | 1997-01-29 | 1998-11-24 | Incyte Pharmaceuticals, Inc. | Prostate-associated kallikrein |
| US6913900B2 (en) | 2001-08-29 | 2005-07-05 | Nippon Zoki Pharmaceutical Co., Ltd. | Plasma prekallikrein activation and kallikrein production assay |
| EP1441589B1 (en) | 2001-11-08 | 2012-05-09 | Abbott Biotherapeutics Corp. | Stable liquid pharmaceutical formulation of igg antibodies |
| ES2528254T3 (es) | 2002-06-07 | 2015-02-05 | Dyax Corp. | Polipéptidos de dominio Kunitz modificado y su uso para reducir la isquemia o el inicio de una respuesta inflamatoria sistémica asociada con un procedimiento quirúrgico |
| US7132100B2 (en) | 2002-06-14 | 2006-11-07 | Medimmune, Inc. | Stabilized liquid anti-RSV antibody formulations |
| EP1674480A4 (en) | 2003-09-04 | 2007-06-20 | Riken | ANTIBODY RECOGNIZING THE REGIONAL SECTION CONTROLLING TGF-BETA ACTIVATION |
| US20070253949A1 (en) | 2004-02-03 | 2007-11-01 | Stefan Golz | Diagnostics and Therapeutics for Diseases Associated with Plasma Kallikrein (KLKB1) |
| US7329737B2 (en) | 2004-08-03 | 2008-02-12 | Dyax Corp. | Antibodies that bind hK-1 |
| US7235530B2 (en) | 2004-09-27 | 2007-06-26 | Dyax Corporation | Kallikrein inhibitors and anti-thrombolytic agents and uses thereof |
| SI2374472T1 (sl) | 2006-03-16 | 2018-11-30 | Dyax Corp., | Sestavki in postopki za zdravljenje oftalmoloških motenj |
| EP2051707B1 (en) | 2006-07-31 | 2013-07-17 | Activesite Pharmaceuticals, Inc. | Inhibitors of plasma kallikrein |
| CN101495468A (zh) * | 2006-07-31 | 2009-07-29 | 艾克提弗赛特制药股份有限公司 | 血浆激肽释放酶抑制剂 |
| KR100846354B1 (ko) | 2007-03-21 | 2008-07-15 | (주) 프로탄바이오 | 혈청 당단백질부터 분리한 폐암 진단용 마커 |
| US8501695B2 (en) * | 2007-07-20 | 2013-08-06 | Diamedica, Inc. | Tissue kallikrein for the treatment of diseases associated with amyloid protein |
| CA2695012A1 (en) | 2007-08-23 | 2009-02-26 | Genzyme Corporation | Treatment with kallikrein inhibitors |
| AU2009266856A1 (en) | 2008-07-02 | 2010-01-07 | Emergent Product Development Seattle, Llc | IL6 immunotherapeutics |
| EP2385843A4 (en) | 2009-01-06 | 2013-02-27 | Dyax Corp | TREATMENT OF MUZOSITIS WITH CALLICINE INHIBITORS |
| CN101928346B (zh) | 2009-07-31 | 2013-01-16 | 华中科技大学同济医学院附属同济医院 | 一种抗人组织激肽释放酶单克隆抗体及其制备 |
| HRP20220107T1 (hr) | 2010-01-06 | 2022-04-15 | Takeda Pharmaceutical Company Limited | Proteini koji vežu kalikrein plazme |
| CN105713092B (zh) | 2011-01-06 | 2019-09-10 | 戴埃克斯有限公司 | 血浆前激肽释放酶结合蛋白 |
| WO2012142308A1 (en) | 2011-04-13 | 2012-10-18 | Activesite Pharmaceuticals, Inc. | Prodrugs of inhibitors of plasma kallikrein |
| KR102136208B1 (ko) | 2011-05-02 | 2020-07-21 | 밀레니엄 파머슈티컬스 인코퍼레이티드 | 항-α4β7 항체에 대한 제형 |
| WO2013123114A2 (en) | 2012-02-16 | 2013-08-22 | Santarus, Inc. | Antibody formulations |
| US9216219B2 (en) | 2012-06-12 | 2015-12-22 | Novartis Ag | Anti-BAFFR antibody formulation |
| KR102419640B1 (ko) | 2013-01-20 | 2022-07-12 | 다케다 파머수티컬 컴패니 리미티드 | pKal 매개 장애의 평가, 검정 및 치료 |
| ES2692408T3 (es) | 2013-01-20 | 2018-12-03 | Dyax Corp. | Evaluación y tratamiento de trastornos mediados por bradiquinina |
| IL292121B2 (en) | 2013-03-15 | 2024-02-01 | Takeda Pharmaceuticals Co | Anti-plasma kallikrein antibodies |
| KR20140119396A (ko) | 2013-03-29 | 2014-10-10 | 삼성전자주식회사 | 단백질 약물의 액상 제형 |
| IL289514B2 (en) | 2013-10-21 | 2024-01-01 | Takeda Pharmaceuticals Co | Assays for determining plasma kallikrein system biomarkers |
| PT3096798T (pt) * | 2014-01-21 | 2021-02-25 | Dyax Corp | Proteínas de ligação à calicreína plasmática e seus usos no tratamento de angioedema hereditário |
| IL247942B (en) | 2014-03-27 | 2022-09-01 | Dyax Corp | Compositions and methods for drops in macular edema as a result of diabetes |
| CN107614532A (zh) | 2015-03-30 | 2018-01-19 | 戴埃克斯有限公司 | 血浆激肽释放酶抑制剂及其预防遗传性血管性水肿发作的用途 |
| KR20250139401A (ko) | 2015-12-11 | 2025-09-23 | 다케다 파머수티컬 컴패니 리미티드 | 혈장 칼리크레인 저해제 및 유전성 혈관부종 발작을 치료하기 위한 이의 용도 |
| CN109716137B (zh) * | 2016-09-16 | 2023-07-21 | 武田药品工业株式会社 | 用于与接触活化系统相关的疾病的代谢产物生物标记 |
| EP3678553B1 (en) | 2017-09-05 | 2024-05-22 | Sanolla Ltd | Diagnosis of pathologies using infrasonic signatures |
| JP7585193B2 (ja) | 2018-08-30 | 2024-11-18 | 武田薬品工業株式会社 | 血漿カリクレイン阻害剤及び遺伝性血管浮腫発作を処置するためのその使用 |
| AU2020237259A1 (en) | 2019-03-14 | 2021-10-14 | Takeda Pharmaceutical Company Limited | Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack |
| CA3167336A1 (en) | 2020-01-13 | 2021-07-22 | Takeda Pharmaceutical Company Limited | Plasma kallikrein inhibitors and uses thereof for treating pediatric hereditary angioedema attack |
-
2015
- 2015-01-21 PT PT157407743T patent/PT3096798T/pt unknown
- 2015-01-21 EP EP20209536.0A patent/EP3848057B1/en active Active
- 2015-01-21 CN CN202310760869.5A patent/CN116585468A/zh active Pending
- 2015-01-21 CA CA2937329A patent/CA2937329C/en active Active
- 2015-01-21 KR KR1020247010766A patent/KR20240049627A/ko active Pending
- 2015-01-21 KR KR1020167022785A patent/KR102424183B1/ko active Active
- 2015-01-21 CN CN201580010172.XA patent/CN106132442B/zh active Active
- 2015-01-21 AU AU2015209481A patent/AU2015209481C1/en active Active
- 2015-01-21 ES ES15740774T patent/ES2856076T3/es active Active
- 2015-01-21 NZ NZ761006A patent/NZ761006A/en unknown
- 2015-01-21 KR KR1020247006911A patent/KR20240033156A/ko active Pending
- 2015-01-21 JP JP2016547570A patent/JP6845012B2/ja active Active
- 2015-01-21 BR BR112016016916-6A patent/BR112016016916B1/pt active IP Right Grant
- 2015-01-21 MX MX2016009428A patent/MX387753B/es unknown
- 2015-01-21 US US15/113,297 patent/US11084884B2/en active Active
- 2015-01-21 PL PL15740774T patent/PL3096798T3/pl unknown
- 2015-01-21 DK DK15740774.3T patent/DK3096798T3/da active
- 2015-01-21 EA EA201691470A patent/EA038532B1/ru unknown
- 2015-01-21 KR KR1020227025028A patent/KR20220107077A/ko not_active Ceased
- 2015-01-21 WO PCT/US2015/012212 patent/WO2015112578A1/en not_active Ceased
- 2015-01-21 EP EP15740774.3A patent/EP3096798B1/en active Active
- 2015-01-21 NZ NZ723369A patent/NZ723369A/en unknown
-
2016
- 2016-07-20 IL IL246864A patent/IL246864B/en active IP Right Grant
- 2016-07-20 MX MX2021013665A patent/MX2021013665A/es unknown
- 2016-08-02 ZA ZA201605342A patent/ZA201605342B/en unknown
-
2018
- 2018-12-12 IL IL263669A patent/IL263669B/en active IP Right Grant
-
2019
- 2019-09-12 JP JP2019166361A patent/JP7164502B2/ja active Active
-
2020
- 2020-07-28 ZA ZA2020/04653A patent/ZA202004653B/en unknown
- 2020-09-02 US US17/010,354 patent/US12384854B2/en active Active
- 2020-09-28 AU AU2020244370A patent/AU2020244370B2/en active Active
- 2020-10-14 IL IL278062A patent/IL278062B/en unknown
-
2022
- 2022-10-20 JP JP2022168140A patent/JP2023015087A/ja active Pending
-
2024
- 2024-05-23 AU AU2024203436A patent/AU2024203436A1/en active Pending
- 2024-09-03 JP JP2024151126A patent/JP2024170495A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL278062B (en) | Plasma kallikrein-binding proteins and their uses in the treatment of hereditary angioedema | |
| ZA201801982B (en) | Method and kit for processing hair | |
| IL259570A (en) | Combined therapy and their uses and methods | |
| IL255463A (en) | Methods and kits for treating depression | |
| ZA201802854B (en) | Authentication methods and sysyems | |
| EP3209298A4 (en) | Compositions and methods for treating insomnia | |
| ZA202108600B (en) | Anti-tnfalpha-antibodies and functional fragments thereof | |
| SG11202000029PA (en) | Anti-tnfalpha-antibodies and functional fragments thereof | |
| IL258863A (en) | Integrin-binding peptides and their use | |
| IL259096A (en) | Peptides and methods of treating endometriosis using the same | |
| ZA201708223B (en) | Endostatin fragments and variants for use in treating fibrosis | |
| IL261261A (en) | Antibodies against tnf-alpha and functional fragments thereof | |
| EP3220908A4 (en) | Compositions and methods for treating endometriosis | |
| IL261098A (en) | Antibodies against tnf-alpha and functional fragments thereof | |
| ZA201901942B (en) | Nnif and nnif-related peptides and related methods | |
| IL261793A (en) | Anti-tnfalpha antibodies and their functional parts | |
| EP3380468B8 (en) | Bis-pyridazine compounds and their use in treating cancer | |
| EP3273970A4 (en) | Methods and materials for treating cancer | |
| EP3331541A4 (en) | Compositions and methods for treating wounds | |
| SI3286013T1 (sl) | Izboljšave v zaščitnih substratih | |
| GB201521209D0 (en) | Title and application in german | |
| EP3110453A4 (en) | Tmem100 peptides and variants thereof and their use in treating or preventing diseases or conditions | |
| HK1259160A1 (en) | Bis-pyridazine compounds and their use in treating cancer | |
| EP3270919A4 (en) | Compositions and methods for treating hepatocellular carcinoma | |
| GB201521083D0 (en) | Compositions for treatment and methods thereof |